Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jul 27:6:205.
doi: 10.3389/fpubh.2018.00205. eCollection 2018.

Health Economic Evaluations of Cancer in Brazil: A Systematic Review

Alessandro G Campolina  1   2   3 , Tania Y Yuba  4 , Tassia C Decimoni  4 , Roseli Leandro  4 , Maria Del Pilar Estevez Diz  1 , Hillegonda M D Novaes  3   4 , Patrícia C de Soárez  3   4
Affiliations

Health Economic Evaluations of Cancer in Brazil: A Systematic Review

Alessandro G Campolina et al. Front Public Health. .

Abstract

Background: A large number of health economic evaluation (HEE) studies have been published in developed countries. However, Brazilian HEE literature in oncology has not been studied.

Objective: To investigate whether the scientific literature has provided a set of HEE in oncology capable of supporting decision making in the Brazilian context. Methods: A systematic review was conducted to identify and characterize studies in this field. We searched multiple databases selecting partial and full HEE studies in oncology (1998-2013). Results: Fifty-five articles were reviewed, of these, 33 (60%) were full health economic evaluations. Type of cancers most frequently studied were: breast (38.2%), cervical (14.6%), lung (10.9%) and colorectal (9.1%). Procedures (47.3%) were the technologies most frequently evaluated. In terms of the intended purposes of the technologies, most (63.6%) were treatments. The majority of the incremental cost-effectiveness ratios (ICERs) reported have been below the cost-effectiveness threshold suggested by the World Health Organization (WHO). Conclusions: There has been an increase in the number of HEEs related to cancer in Brazil. These studies may support decision-making processes regarding the coverage of and reimbursement of healthcare technologies for cancer treatment in Brazil.

Keywords: Brazil; cost-benefit analysis; costs and cost analysis; health care costs; neoplasms.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow diagram of the process for the selection of health economic evaluations related to cancer in Brazil, 1998–2013. Bireme, Biblioteca Regional de Medicina (Regional Library of Medicine); BVS ECOS, Biblioteca Virtual em Saúde Economia da Saúde (Health Economics [database] of the [Brazilian] Virtual Library of Health); EED, Economic Evaluation Database; EMBASE, Excerpta Medica; JBES, Jornal Brasileiro de Economia da Saúde (Brazilian Journal of Health Economics); LILACS, Latin American and Caribbean Health Sciences Literature; SciELO, Scientific Electronic Library Online; SISREBRATS, Sistema de Informação da Rede Brasileira de Avaliação de Tecnologias em Saúde (Brazilian Network for the Evaluation of Health Technologies).
Figure 2
Figure 2
Number and proportional distribution of health economic evaluations related to cancer in Brazil, by publication date and type, 1998–2013.
Figure 3
Figure 3
ICERs per QALY gained, in United States Dollars (at 2013 rates), reported in health economic evaluations related to cancer in Brazil, 1998–2013 (× USD 1,000). *1× per capita GDP = USD 14,588.62; 3× per capita GDP = USD 43,765.86 (2013). CAP, capecitabine; LAP, lapatinib; mFLOX, modified 5-fluorouracil, leucovorin, and oxaliplatin; mFOLFOX6, modified 5-fluorouracil, folinic acid, and oxaliplatin (mFOLFOX6); NMPOA, Núcleo Mama Porto Alegre (Breast Center of Porto Alegre); SFM, screen-film mammography; FFDM, full-field digital mammography; TRAST, trastuzumab.
Figure 4
Figure 4
ICERs per life year gained, in United States Dollars (at 2013 rates), reported in health economic evaluations related to cancer in Brazil, 1998–2013 (× USD 1,000). *1× per capita GDP = USD 14,588.62; 3× per capita GDP = USD 43,765.86 (2013). 5-FU/LV, 5-fluorouracil plus leucovorin; FOLFIRI, folinic acid, 5-fluorouracil, and irinotecan; FOLFOX, 5-fluorouracil, folinic acid, and oxaliplatin; MRI, magnetic resonance imaging.
See this image and copyright information in PMC

References

    1. Strasser-Weippl K, Chavarri-Guerra Y, Villarreal-Garza C, Bychkovsky BL, Debiasi M, Liedke PER, et al. Progress and remaining challenges for cancer control in Latin America and the Caribbean. Lancet Oncol. (2015) 16:1405–38. 10.1016/S1470-2045(13)70048-2 - DOI - PubMed
    1. Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA) Estimativa 2018: Incidência de Câncer no Brasil. Coordenação de Prevenção e Vigilância (2017). Available online at: http://www2.inca.gov.br/wps/wcm/connect/en-inca/portal/home
    1. American Society of Clinical Oncology (ASCO) Major Cancer Milestones. American Society of Clinical Oncology. (2014). Available online at: https://www.asco.org/research-progress/cancer-progress-timeline
    1. Novaes HMD, de Soárez PC. Organizaciones de evaluación de tecnologías en salud (ETS): dimensiones del marco institucional y político. Cad Saúde Pública. (2016) 32:S1–14. 10.1590/0102-311X00022315 - DOI - PubMed
    1. Drummond M, Sculpher M, Torrance G, O'Brien B SG. Methods for the Economic Evaluation of Health Care Programmes. New York, NY: Oxford University Press; (2015).

LinkOut - more resources